LGND:NASDAQ
Ligand Pharmaceuticals Inc
$302.96
arrow_upward
+0.07%(+0.22) 1D
$302.96
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LGND...
Open
$307.55
High
$307.63
Low
$301.32
Mkt. cap
6.04B
Avg. vol.
236.03K
Volume
179.23K
P/E ratio
32.22
52-wk high
$326.63
52-wk low
$175.89
EPS
$9.40
Beta
1.06
Shares outstanding
19.94M
No. of employees
47
Open
$307.55
High
$307.63
Low
$301.32
Mkt. cap
6.04B
Avg. vol.
236.03K
Volume
179.23K
P/E ratio
32.22
52-wk high
$326.63
52-wk low
$175.89
EPS
$9.40
Beta
1.06
Shares outstanding
19.94M
No. of employees
47
News stories
From web sources and news partners
marketscreener.com
·
57 minutes ago
S&P holds Romania rating, expects credible budget framework
BigGo Finance
·
1 hour ago
U.S. 10-Year Yield Tops 5.3%: S&P 500 Looks Solid on the Surface, But Five Major Sectors Are Already Cracking
TradingView
·
1 hour ago
Nasdaq rises for the week as Lumentum leads gains
U.S. Global Investors
·
1 hour ago
Gold Stumbled in September, but Gold Miners Beat Every Sector in the S&P 500
Profile
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
About Ligand Pharmaceuticals Inc
CEO-
Employees47
FoundedSep 1987
HeadquartersJupiter, Florida, United States
SectorPharmaceutical industry
Websiteligand.com